Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 98 peer-reviewed journal articles Updated
Hematology · Graft-Versus-Host Disease

Understanding Graft-Versus-Host Disease (GVHD)

At a Glance

Graft-Versus-Host Disease (GVHD) is an expected condition after a stem cell transplant where new donor immune cells attack your healthy tissues. Developing GVHD does not mean your transplant failed; it shows your new immune system is active and can help fight off remaining cancer cells.

Undergoing an allogeneic stem cell transplant is a monumental journey, and it is completely normal to feel a mix of hope and intense anxiety as you wait for your new immune system to “take hold.” If you are hearing the term Graft-Versus-Host Disease (GVHD), it can feel like a setback. However, understanding what is happening in your body can help transform that fear into a sense of partnership with your medical team.

This guide is designed to empower you with the latest evidence-based information on GVHD. Below is a summary of what you need to know, with links to deeper dives into specific topics.

What is GVHD?

In simple terms, Graft-Versus-Host Disease (GVHD) occurs when the “graft” (the donated stem cells) sees the “host” (your body) as different or foreign [1][2].

When you received your transplant, you didn’t just receive new blood cells; you received a brand-new immune system. The job of an immune system is to identify and attack anything it doesn’t recognize, such as bacteria or viruses. Sometimes, these new donor immune cells—specifically T cells—mistake your own healthy tissues for “foreign” invaders and begin to attack them [1][3]. This is why GVHD is most commonly seen in areas that are “exposed” to the outside world, such as your skin, your gut (digestive tract), and your liver [4][2].

Why This Happens

GVHD is a recognized and expected part of the transplant process, occurring in roughly 30% to 70% of patients [5][6]. It is not a sign that your body is “rejecting” the transplant. In fact, it is the opposite: it is a sign that the donor’s immune system is active and working. While the goal is to keep this activity at a manageable level, the presence of some GVHD often means the donor cells are also capable of finding and destroying any remaining cancer cells—a beneficial process doctors call the Graft-versus-Leukemia (GvL) effect.

Three Stabilizing Facts

When you are first navigating a GVHD diagnosis or the risk of one, keep these three facts in mind to help stay grounded:

  1. It Is Not a Failure: Developing GVHD does not mean your transplant has failed or that your body is “fighting” the new cells [5]. It is a sign of an active, vigorous donor immune system that is successfully engrafting (setting up shop) in your bone marrow.
  2. Treatment is Highly Standardized: GVHD is one of the most studied complications in transplant medicine. Doctors have well-established, “consensus” guidelines for treating it [7][8]. If the first treatments don’t work as well as hoped, there are now several highly effective “second-line” therapies, such as ruxolitinib, which have shown very high response rates [9][10].
  3. Survival Rates are Improving: Thanks to better monitoring, faster diagnosis, and new medications, the outcomes for patients with GVHD have improved significantly [11][12]. Your team is trained to catch the very first signs of GVHD to start treatment early [13][14].

Looking Ahead: Acute vs. Chronic

Historically, GVHD was categorized simply by when it appeared (before or after 100 days). Today, doctors understand that it is better defined by the symptoms and the organs it targets:

  • Acute GVHD: This typically causes sudden, inflammatory symptoms—often an angry red skin rash, nausea, or watery diarrhea [1][4]. While it usually occurs early (within 100 days), it can happen later.
  • Chronic GVHD: This behaves more like an autoimmune condition, potentially causing tightness in the skin, dry eyes, mouth sores, joint stiffness, or lung changes [4][15]. It usually develops later in the recovery journey.

Explore the Guide

Use the links below to dive deeper into specific aspects of GVHD and learn how to navigate your care:

01

The Biology of GVHD: Why and How It Happens

Learn about the biology of Graft-Versus-Host Disease (GVHD). Understand how T cells, the STING pathway, and gut microbiome affect acute and chronic GVHD.

02

Signs to Watch For: Symptoms and Warning Signs

Learn the early warning signs of acute and chronic GVHD. Understand skin rashes, GI symptoms, liver changes, and when to seek emergency medical care.

03

Diagnosis and Staging: Making Sense of the Scores

Learn how doctors diagnose and stage Graft vs Host Disease (GVHD). Understand the MAGIC criteria, MAP score, and NIH severity scores for your treatment.

04

Prevention and Prophylaxis: Stopping GVHD Before It Starts

Learn how graft-versus-host disease (GVHD) is prevented after a stem cell transplant. Understand prophylaxis medications like PTCy, tacrolimus, and ATG.

05

Treatment Strategies: When GVHD Happens

Learn about Graft versus Host Disease (GVHD) treatment options, from first-line corticosteroids to new targeted therapies for steroid-refractory GVHD.

06

Survivorship & Daily Management: Living with Chronic GVHD

Learn how to manage daily life with chronic GVHD. Discover how to build your care team, relieve physical symptoms, and navigate the emotional toll of recovery.

Common questions in this guide

What is Graft-Versus-Host Disease (GVHD)?
GVHD occurs when donated stem cells from an allogeneic transplant recognize your body's healthy tissues as foreign and begin to attack them. It is a common part of the transplant process, usually affecting areas exposed to the outside world like the skin, gut, and liver.
Does developing GVHD mean my stem cell transplant failed?
No, developing GVHD does not mean your transplant has failed or is being rejected. In fact, it indicates that your new donor immune system is active and working, which can also help destroy any remaining cancer cells in your body.
What is the difference between acute and chronic GVHD?
Acute GVHD typically causes sudden inflammation, such as red skin rashes or watery diarrhea, and usually appears early in recovery. Chronic GVHD behaves more like an autoimmune condition, causing symptoms like tight skin, dry eyes, or joint stiffness, and tends to develop later.
Are there effective treatments for GVHD if it develops?
Yes, GVHD is one of the most studied complications in transplant medicine and has well-established treatment guidelines. If initial therapies do not work as hoped, doctors have highly effective second-line medications, such as ruxolitinib, to manage symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the GVHD I'm experiencing considered mild, and does this mean my donor's cells are effectively fighting any remaining cancer (the Graft-versus-Leukemia effect)?
  2. 2.What specific early symptoms, like skin changes or digestive issues, should I be monitoring most closely right now?
  3. 3.If my current GVHD treatment needs to be adjusted, what are the next-step options, such as ruxolitinib?
  4. 4.How does my current immune suppression regimen balance the need to treat GVHD while still protecting me from infections?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Acute graft-vs-host disease, pathophysiology, prevention, and treatment: Something old and something new.

    Cohan N, Ramzi M, Dermarderosian A, Akhtari M

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2026; (74(1)):3-15 doi:10.1177/10815589251359314.

    PMID: 40621931
  2. 2

    Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

    Zeiser R, Blazar BR

    The New England journal of medicine 2017; (377(22)):2167-2179 doi:10.1056/NEJMra1609337.

    PMID: 29171820
  3. 3

    STING and transplantation: can targeting this pathway improve outcomes?

    Bader CS, Jin L, Levy RB

    Blood 2021; (137(14)):1871-1878 doi:10.1182/blood.2020008911.

    PMID: 33619537
  4. 4

    Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.

    Bhattarai A, Shah S, Yadav R, et al.

    Hematology (Amsterdam, Netherlands) 2024; (29(1)):2293497 doi:10.1080/16078454.2023.2293497.

    PMID: 38112182
  5. 5

    ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD.

    Akirov A, Sawka AM, Ben-Barouch S, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(5)):485-490 doi:10.4158/EP-2018-0529.

    PMID: 30657358
  6. 6

    A Case Report of Central Nervous System Graft-Versus-Host Disease and Literature Review.

    Li M, Zhang Y, Guan Y, et al.

    Frontiers in neurology 2021; (12()):621392 doi:10.3389/fneur.2021.621392.

    PMID: 33776885
  7. 7

    [Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(8)):713-726 doi:10.3760/cma.j.cn121090-20240611-00217.

    PMID: 39307718
  8. 8

    [Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(6)):525-533 doi:10.3760/cma.j.cn121090-20240608-00214.

    PMID: 39134482
  9. 9

    Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.

    Sanli NM, Karakuş E

    Hematology, transfusion and cell therapy 2025; (47(3)):103835 doi:10.1016/j.htct.2025.103835.

    PMID: 40354779
  10. 10

    Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

    Penack O, Marchetti M, Aljurf M, et al.

    The Lancet. Haematology 2024; (11(2)):e147-e159 doi:10.1016/S2352-3026(23)00342-3.

    PMID: 38184001
  11. 11

    Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.

    Greinix HT, Eikema DJ, Koster L, et al.

    Haematologica 2022; (107(5)):1054-1063 doi:10.3324/haematol.2020.265769.

    PMID: 34162176
  12. 12

    [Congenital neutropenia and acute graft-versus-host disease in an infant. A case report].

    Huchim-Peña CJ, Catana-Gallegos E, Martín-Burgos NG, Pacheco-Sierra JEA

    Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2024; (71(4)):268-271 doi:10.29262/ram.v71i4.1405.

    PMID: 39752270
  13. 13

    A clinical and histological comparison between acute cutaneous graft-versus-host disease and other maculopapular eruptions following hematopoietic stem cell transplantation: a retrospective cohort.

    Chanprapaph K, Leerunyakul K, Niparuck P, Rutnin S

    International journal of dermatology 2021; (60(1)):60-69 doi:10.1111/ijd.15186.

    PMID: 32989780
  14. 14

    Case report: An unusual presentation of oral acute graft-versus-host-disease in a haploidentical hematopoietic stem cell transplant recipient.

    Hong C, Tang KS, Villegas M, Tan PL

    Oral surgery, oral medicine, oral pathology and oral radiology 2016; (121(3)):e51-3.

    PMID: 26868474
  15. 15

    Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.

    Mirgh S, Gokarn A, Punatar S, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(4)):e13576 doi:10.1111/tid.13576.

    PMID: 33523551

This overview of Graft-Versus-Host Disease is for educational purposes only. Always consult your transplant team regarding specific symptoms, medication adjustments, and your individual care plan.

Get notified when new evidence is published on Graft versus host disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.